Pharmaceuticals company Fermenta Biotech announced Q2FY27 results Standalone Financial Highlights: Revenue from Operations: Standalone revenue from operations stood at Rs 11,693.63 lakh for Q2FY27, showing a QoQ growth of 4.56% compared to Rs 11,183.93 lakh in Q1FY27 and a YoY growth of 9.17% compared to Rs 10,711.52 lakh in Q2FY26. For H1FY27, revenue from operations was Rs 22,877.56 lakh, registering a YoY increase of 1.17% from Rs 22,613.39 lakh in H1FY26. Total Income: Total income reached Rs 12,058.55 lakh for Q2FY27, increasing by 3.30% QoQ from Rs 11,673.59 lakh in Q1FY27 and by 7.05% YoY from Rs 11,264.31 lakh in Q2FY26. For H1FY27, total income stood at Rs 23,732.14 lakh, experiencing a minor YoY decrease of 1.32% against Rs 24,050.26 lakh in H1FY26. Profit Before Tax (PBT): PBT was reported at Rs 1,876.57 lakh for Q2FY27, dropping by 6.85% QoQ from Rs 2,014.58 lakh in Q1FY27 and by 9.66% YoY from Rs 2,077.21 lakh in Q2FY26. For H1FY27, PBT was Rs 3,891.15 lakh, representing a YoY decline of 10.53% from Rs 4,349.13 lakh in H1FY26. Profit After Tax (PAT): PAT stood at Rs 1,395.36 lakh for Q2FY27, decreasing by 6.89% QoQ compared to Rs 1,498.58 lakh in Q1FY27 and decreasing by 5.19% YoY compared to Rs 1,471.79 lakh in Q2FY26. For H1FY27, PAT was Rs 2,893.94 lakh, lower by 6.50% YoY against Rs 3,095.17 lakh in H1FY26. Earnings Per Share (EPS): Basic EPS for Q2FY27 was Rs 4.86, showing a QoQ decrease of 7.07% from Rs 5.23 in Q1FY27 and a YoY decrease of 3.76% from Rs 5.05 in Q2FY26. For H1FY27, basic EPS was Rs 10.09, showing a YoY decrease of 4.90% from Rs 10.61 in H1FY26. Consolidated Financial Highlights: Revenue from Operations: Consolidated revenue from operations was recorded at Rs 13,267.44 lakh for Q2FY27, representing a QoQ growth of 8.91% against Rs 12,182.12 lakh in Q1FY27 and a YoY growth of 1.88% from Rs 13,022.27 lakh in Q2FY26. For H1FY27, consolidated revenue dropped by 4.50% YoY to Rs 25,449.56 lakh compared to Rs 26,648.54 lakh in H1FY26. Total Income: Total income was Rs 13,575.70 lakh for Q2FY27, climbing 7.58% QoQ from Rs 12,619.50 lakh in Q1FY27 and remaining nearly flat with a 0.07% YoY shift from Rs 13,565.56 lakh in Q2FY26. For H1FY27, total income declined by 6.68% YoY to Rs 26,195.20 lakh from Rs 28,068.96 lakh in H1FY26. Profit Before Tax (PBT): PBT came in at Rs 1,424.94 lakh for Q2FY27, down 3.01% QoQ from Rs 1,469.15 lakh in Q1FY27 and down 40.83% YoY from Rs 2,408.34 lakh in Q2FY26. For H1FY27, PBT dropped by 44.53% YoY to Rs 2,894.09 lakh from Rs 5,217.05 lakh in H1FY26. Profit After Tax (PAT): Net profit after tax was Rs 943.72 lakh for Q2FY27, a marginal decline of 0.99% QoQ from Rs 953.15 lakh in Q1FY27 and a decline of 47.66% YoY from Rs 1,802.92 lakh in Q2FY26. For H1FY27, PAT fell by 52.14% YoY to Rs 1,896.87 lakh from Rs 3,963.09 lakh in H1FY26. Earnings Per Share (EPS): Basic EPS stood at Rs 3.41 for Q2FY27, up 0.29% QoQ from Rs 3.40 in Q1FY27 but down 47.38% YoY from Rs 6.48 in Q2FY26. For H1FY27, basic EPS was Rs 6.80, a decrease of 51.29% YoY compared to Rs 13.96 in H1FY26. Business Highlights & Segment Performance: Bulk Drugs/Chemicals Segment: Consolidated revenue for this segment was Rs 12,230.79 lakh in Q2FY27 compared to Rs 11,739.16 lakh in Q1FY27 and Rs 12,402.63 lakh in Q2FY26. For H1FY27, revenue reached Rs 23,969.95 lakh compared to Rs 25,792.52 lakh in H1FY26. Consolidated segment results recorded a profit of Rs 1,897.91 lakh in Q2FY27 and Rs 3,802.96 lakh in H1FY27. Property Segment: Consolidated property revenue tracked identical to standalone figures at Rs 198.38 lakh in Q2FY27 and Rs 397.74 lakh for H1FY27. Segment results posted a profit of Rs 1.17 lakh in Q2FY27 and Rs 8.01 lakh in H1FY27. Environment Segment: Identified as a separate reportable segment during the quarter, it posted revenue of Rs 1,071.87 lakh in Q2FY27 compared to Rs 599.01 lakh in Q1FY27 and Rs 860.45 lakh in Q2FY26. For H1FY27, revenue stood at Rs 1,670.88 lakh compared to Rs 1,526.68 lakh in H1FY26. This segment recorded a consolidated loss of Rs (175.50) lakh in Q2FY27 and Rs (446.30) lakh in H1FY27. Prashant Nagre, Managing Director, said: “The first half tested the balance of our business. Vitamin D3 prices in animal nutrition fell by about a third, and the comparison year carried income that did not repeat. Through that, Human Nutrition, now close to two-thirds of our revenue, grew 2%, and its volumes rose 7% sequentially over Q1FY27, strengthening Fermenta’s focus on Human Nutrition. India is now our largest market, at 51% of revenue. The FSSAI approval for VITADEE Green® opens the country’s large vegetarian consumer base to a domestically manufactured, patentbacked Vitamin D3, the capacities for which should be available from Q2FY28. Vitamin D3 analog product Calcifediol is expected to be ready for regulatory approvals by the end of FY27. Our listing on the NSE has broadened access to Fermenta for investors.” Result PDF